Skip to content

Evaluation of the effect of ivermectin in intubated patients 19

Evaluation of the effect of adding ivermectin to standard therapies on the outcome of intubated Covid-19 patients under ventilator

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190417043295N2
Enrollment
40
Registered
2021-09-20
Start date
2021-09-23
Completion date
Unknown
Last updated
2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, virus not identified. COVID-19, virus not identified

Interventions

Intervention 1: Intervention group:In addition to the drugs prescribed according to the national protocol, Receiving Ivermectin, 6 mg twice daily on the first day and 3 mg twice daily on the second to

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Covid PCR test 19 positive Intubated patient No increase in liver enzymes

Exclusion criteria

Exclusion criteria: History of drug allergy Pregnant Women Withdrawal of the patient's family from continuing to participate in the study

Design outcomes

Primary

MeasureTime frame
Mortality rate. Timepoint: 30 days range, Daily from the time the patient enters the study. Method of measurement: Vital sign check in 30 days range.

Secondary

MeasureTime frame
Intubation period. Timepoint: in 30 day range, Daily from the time the patient enters the study. Method of measurement: Visual Observation.;Lung Compliance. Timepoint: Daily from the time the patient enters the study. Method of measurement: Calculated based on ventilator data.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Baghbanian

Ahvaz University of Medical Sciences

baghbanian.r@ajums.ac.ir+98 61 3292 3985

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026